Therefore, various novel strategies to regulate the SIRT1–PARP1 axis either directly or indirectly may demonstrate therapeutic potential in attenuating senescence and apoptosis, which are known to be involved in aging and aging-related diseases. This evidence concerns the gene PARP1 and glycogen storage disease VI.